Clinical Commander

All dossiers
cardio.atrial_flutter.post-cardiac-surgery.v1

Atrial flutter / atrial tachycardia — post-cardiac-surgery (POAF)

cardiologyacuteadultacuteinpatienttransitionoutpatient
Start encounter →Print handoutPRODUCTION

Phase E variant of cardio.atrial_flutter.v1 — narrowed to post-cardiac-surgery cohort (POAF). Incidence 20-50% CABG, 30-60% mitral surgery, 50-70% MAZE; peak postop day 2-4. Multifactorial substrate: pericardial inflammation + sympathetic surge + cardioplegia-associated K + Mg depletion + atrial cannulation injury + transient ischemia. Usually self-limiting with >80% reverting to sinus by 6-8 wk. Treatment: hemodynamically unstable → DCCV 200J biphasic; stable RVR → IV BB (esmolol or metoprolol); diltiazem second-line; symptomatic stable → amiodarone load + 4-6 wk maintenance; persistent >48h → AC bridge then DOAC × 3 mo time-limited. Prevention: PAPABEAR-derived preop amiodarone OR low-dose colchicine 0.5 mg PO BID × 1 mo per COPPS-2 (PMID 25268438) — reduces POAF AND post-pericardiotomy syndrome. Inherits manifest + design-brief pointer from parent cardio.atrial_flutter.v1. 5 setting playbooks (ed, icu, inpatient, transition, outpatient). 4 severity triggers including atrioesophageal fistula post-cardioversion concern. Status INTEGRATED until terminology + RxNav-validated drug codes are reconciled. Authored 2026-05-15 by shard-06-cardio-acute Phase E wave 14.

Entry points (3)

  • history
    New atrial flutter on telemetry postoperative day 2–4 after CABG, valve surgery, or MAZE — peak POAF onset window (STS 2024)
    new_aflutter_postop_day_2_to_4_cardiac_surgery
  • history
    Atrial flutter with RVR after mitral surgery — incidence 30–60% per LaPar JTCVS 2014; coordinated with cardiac surgery team
    aflutter_with_rvr_post_mitral_surgery
  • history
    Recurrent atrial flutter after surgical MAZE procedure — incidence 50–70% in early postop period; reflects atrial scar substrate plus inflammation
    recurrent_aflutter_after_surgical_maze

Required inputs (15)

  • agerequired
    demographic • used at CONTEXT
    Age >75 = higher POAF incidence + higher bleed risk on bridging AC; pediatric post-cardiac-surgery distinct (rare congenital surgery cohort, separate engine)
  • surgery_type_and_postop_dayrequired
    history • used at CONTEXT
    CABG (20–50% incidence) vs mitral surgery (30–60%) vs MAZE (50–70%) — informs prophylaxis aggressiveness, expected duration, and reversion likelihood; postop day 2–4 = peak window
  • sbprequired
    vital • used at RED_FLAGS
    Hemodynamic stability is the dominant treatment-arm driver: SBP <90 with RVR → emergent DCCV; SBP >90 → IV rate control
  • hrrequired
    vital • used at CONTEXT
    RVR >130 with hemodynamic compromise → emergent DCCV; HR 100–130 + stable → IV rate control; target HR 80–110 for chronic rate control
  • ecg_12_leadrequired
    imaging • used at INITIAL_WORKUP
    Confirms flutter morphology (typical CTI-dependent vs atypical incisional from atriotomy); rules out ischemic substrate from new postop ACS; QTc baseline pre-amiodarone or sotalol
  • tte_postop_baselinerequired
    imaging • used at INITIAL_WORKUP
    Post-surgical LVEF + LA size + valve status (especially if mitral surgery); EF <40 contraindicates non-DHP CCB; pericardial effusion screen for post-pericardiotomy syndrome
  • tee_within_48h_pre_dccv_if_persistent_>48h
    imaging • used at TREATMENT
    EXCLUDE LAA thrombus pre-DCCV when AFL persistent >48h and AC not therapeutic ≥3 wk — ACC/AHA 2024 (PMID 38753446); deferred DCCV if thrombus present
  • creatinine_egfrrequired
    lab • used at INITIAL_WORKUP
    DOAC + amiodarone + metoprolol dose adjustment; bridge LMWH dose adjustment (enoxaparin renal-adjusted CrCl <30); pre-op baseline often available
  • potassium_magnesiumrequired
    lab • used at INITIAL_WORKUP
    Cardioplegia + postop diuresis depletes K + Mg → arrhythmogenic substrate; replete K to 4.0–4.5 + Mg to 2.0–2.5 as foundational treatment per AATS 2014 (PMID 24290998)
  • troponin_postop_baselinerequired
    lab • used at INITIAL_WORKUP
    Post-CABG troponin baseline differentiates POAF-only from POAF + new ischemia; 5x ULN postop is normal range; serial trending if rising
  • tsh_lft_pre_amiorequired
    lab • used at INITIAL_WORKUP
    Amiodarone toxicity baseline (TFTs, LFTs) — required pre-amiodarone load especially if planned >4 wk postop course
  • cha2ds2_vasc_factorsrequired
    history • used at RISK_STRATIFICATION
    AC indication + duration: 3 mo time-limited if reverts to sinus and no recurrence vs lifelong if structural substrate
  • bleeding_history_postoprequired
    history • used at RISK_STRATIFICATION
    HAS-BLED + recent surgical bleed risk (chest tube output, hematoma, pericardial effusion); drives bridging AC hesitancy in early postop period
  • preop_amiodarone_or_colchicine_prophylaxis
    history • used at CONTEXT
    PAPABEAR (PMID 15998893) preop amiodarone or COPPS-2 (PMID 25268438) colchicine prophylaxis status — informs prevention success or failure narrative
  • pericardial_effusion_or_tamponade_screenrequired
    history • used at RED_FLAGS
    Post-pericardiotomy syndrome with effusion / tamponade can present as POAF + hemodynamic compromise; bedside echo to exclude

12-phase flow (11)

  1. 1FRAME
    Post-cardiac-surgery AFL/AT (POAF) — incidence 20–70% by surgery type, peak postop day 2–4, multifactorial substrate (pericardial inflammation + sympathetic surge + electrolyte shifts + atrial cannulation injury); usually self-limiting >80% revert by 6–8 wk; route to parent cardio.atrial_flutter.v1 for AC + acute rate management
    inputs: surgery_type_and_postop_day, ecg_12_lead
    advance: POAF mechanism + surgery context documented
  2. 2ENTRY
    New AFL on telemetry postop day 2–4 OR persistent AFL beyond expected window; coordinate with cardiac surgery team
    inputs: age, surgery_type_and_postop_day
    advance: POAF identified + surgery team notified
  3. 3CONTEXT
    Surgery type, postop day, HR/BP trajectory, K + Mg status, prior AF/AFL history, preop prophylaxis (amiodarone or colchicine), chest tube output / bleeding postop, current AC therapy, structural cardiac substrate (LA size, EF), comorbidities
    inputs: hr, cha2ds2_vasc_factors, bleeding_history_postop, preop_amiodarone_or_colchicine_prophylaxis
    advance: context complete
  4. 4RED_FLAGS
    Hemodynamic instability with RVR (SBP <90, pulmonary edema, ischemia) → urgent DCCV; pericardial effusion / tamponade → emergent drainage; postop bleeding → hold AC; refractory hyperkalemia or severe acidosis from low-output state
    inputs: sbp, pericardial_effusion_or_tamponade_screen
    actions: tachycardia, cardiogenic_shock
    advance: red flags screened + escalations triggered
  5. 5INITIAL_WORKUP
    ECG + BMP/Mg + TSH/LFTs (amiodarone screen) + creatinine + CBC + postop troponin + bedside echo for effusion + LV function + chest tube output review + coag panel pre-AC bridge
    inputs: ecg_12_lead, tsh_lft_pre_amio, creatinine_egfr, potassium_magnesium, troponin_postop_baseline, tte_postop_baseline
    actions: panel.cardiac, panel.thyroid, panel.renal
    advance: workup complete + effusion ruled out + electrolytes optimized
  6. 6BRANCHING_WORKUP
    TEE within 48h pre-DCCV if AFL persistent >48h and AC not therapeutic ≥3 wk; coronary workup if new ischemic ECG changes (rare in POAF only); concomitant AF on monitor → also route cardio.afib.core.v1; post-pericardiotomy syndrome → NSAID + colchicine extension
    inputs: tee_within_48h_pre_dccv_if_persistent_>48h
    actions: afib_new_onset, acs_pathway
    advance: branch resolved
  7. 7RISK_STRATIFICATION
    CHA2DS2-VASc (AC indication); HAS-BLED (postop bleed risk modifier); structural substrate assessment (LA enlargement, prior atrial scar) → drives 3-mo time-limited vs lifelong AC decision
    inputs: cha2ds2_vasc_factors, bleeding_history_postop
    advance: tier + AC duration plan documented
  8. 8TREATMENT
    Hemodynamically unstable → DCCV 200 J biphasic; stable RVR → IV BB (esmolol bolus 0.5 mg/kg → 50–300 µg/kg/min infusion; or metoprolol 5 mg IV q5 min × 3); diltiazem second-line if BB contraindicated AND EF preserved; symptomatic but stable → amiodarone 150 mg IV → 1 mg/min × 6h → 0.5 mg/min × 18h → 200 mg PO daily; persistent >48h → AC bridge (heparin or LMWH) → DOAC (apixaban preferred) per CHA2DS2-VASc; AC duration 3 mo if reverts AND no recurrence (longer if structural substrate); K + Mg repletion FOUNDATIONAL — ACC/AHA 2024 (PMID 38753446) + AATS 2014 (PMID 24290998) + STS 2024
    inputs: hr, creatinine_egfr, potassium_magnesium
    advance: treatment arm initiated + AC bridge plan documented
  9. 9DISPOSITION
    Continue cardiac surgery floor monitoring; CICU transfer if hemodynamic instability or pericardial effusion drainage required; coordinate with cardiac surgery team for chest tube management + AC timing
    advance: unit + service-line ownership documented
  10. 10MONITORING
    Continuous telemetry × 48–72h post-conversion; daily K + Mg with repletion; QTc q24h on amiodarone or sotalol; chest tube output trend; bedside echo q24–48h to monitor effusion; 30-d Holter or implantable loop recorder if persistent
    inputs: ecg_12_lead, potassium_magnesium
    advance: monitoring orders documented + 30-d follow-up plan in place
  11. 11FOLLOWUP
    Cardiac surgery + cardiology follow-up at 2 wks postop with ECG; cardiology at 4–6 wk for rhythm assessment + AC continuation decision; Holter at 3 mo to document sinus maintenance; AC STOP at 3 mo if reverts AND no recurrence on Holter; cardiac rehab booked; post-pericardiotomy syndrome surveillance with NSAID + colchicine if effusion present
    advance: follow-up + Holter + AC duration decision booked